Replies to post #5469 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Algernon Pharmaceuticals Intellectual Property – Device Program

Annual Information Form

For The Financial Year Ended August 31, 2018

April 11, 2019

Page 28

On June 18, 2016, the Company signed a license agreement with the University of Florida Research Foundation, a non-profit Florida corporation (“UFRF”) with respect to an exclusive royalty-bearing license to certain UFRF patent rights and a non-exclusive royalty bearing license to certain UFRF know-how to enable commercial advancements in the field of infections detection.

Pursuant to the terms of the license agreement, the URFR license is effective from June 18, 2016 to the later of the date that no patent right remains enforceable and ten years after the first commercial sale of a licensed product (with an option to extend for additional five-yearterms).

https://webfiles.thecse.com/sedar_filings/00037722/1904160953176150.pdf

/////AMG